AlphAIAlphAI — Financial news for AI agents
investing.comNOV 22 min read$BMRN

Biomarin earnings on deck: Amicus integration in focus

BioMarin Pharmaceutical (BMRN) reports Q3 earnings with investors focusing on Amicus integration. Analysts expect $1.35 EPS on $1.02B revenue. The stock has a Buy rating, $91.56 target, and recent upgrades. Key areas include Amicus cost synergies, VOXZOGO growth, and pipeline developments. Q2 showed strong earnings and revenue beats.

Original reporting
investing.com
Published Nov 2, 2026, 4:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 4:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BMRN
Neutral
high confidence
Mentioned
$BMRN
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BMRNNeutralHigh
01

Why it matters

The earnings release will test whether cost synergies materialize and if the expanded portfolio drives top‑line growth.

02

Market read

First‑time Q3 earnings data for BioMarin provides actionable insight for biotech traders; integration cost visibility is the key catalyst.

03

What to watch

Potential regulatory scrutiny of the $4.8B Amicus acquisition and upcoming pipeline milestones.

Relevance 8/10Novelty 8/10Timing: Monday post‑market earnings release

Background

BioMarin completed its $4.8 billion Amicus Therapeutics acquisition in April 2026 and is now integrating new enzyme therapies while guiding higher revenue for its VOXZOGO product.

Company-level read

Ticker impact

$BMRNNeutralHigh confidence
Context

BioMarin Pharmaceutical Inc. will report Q3 earnings Monday after market close, with new EPS and revenue estimates and integration cost details.

Expected impact

possible upside if earnings beat expectations; pressure if integration costs weigh on profit.

Evidence & confidence

First report of the quarter's numbers provides fresh data; analysts have raised EPS estimates, indicating market sensitivity.

Market effects

Sector

Rare‑disease biotech sector may see broader sentiment shift based on BioMarin's integration progress.

Regional

U.S. biotech stocks could react to the earnings beat or miss.

Global

Limited to biotech investors; no broad macro impact.

Counterpoint

What could challenge this read

If integration costs exceed expectations, the stock could face a sell‑off despite earnings beat.

Key entities

  • company
    BioMarin Pharmaceutical Inc.

    U.S. rare‑disease biotech reporting Q3 earnings.

  • company
    Amicus Therapeutics

    Acquired rare‑disease biotech now part of BioMarin.

Read at source← All news

StoryBioMarin posts Q3 2026 revenue above $1 billion but trims full‑year outlook

Also covered by

5 outlets

Related articles

NOV 3
$BMRNHighAI 8/10

BioMarin reports Q3 revenue beat but cuts full-year outlook

BioMarin Pharmaceutical (BMRN) reported Q3 revenue of $1.025B, beating estimates. EPS matched expectations at $0.23. The company lowered full-year revenue guidance by $50M and fiscal 2026 earnings guidance to $2.80-$3.10 per share, citing delays in Voxzogo orders and business development impacts. Management expects faster cost synergies from the Amicus acquisition.

investing.com2 min
NOV 3
$BMRNHighAI 8/10

BioMarin (BMRN) Q3 2026 Earnings Call Transcript

BioMarin (BMRN) reported Q3 2026 revenue growth of 44% in metabolic conditions, driven by Galafold, Pombility, and Opfolda, which generated over $200M combined. VOXZOGO saw a 17% increase in treated patients. The company updated guidance, citing order timing and geopolitical headwinds, and highlighted pipeline advancements like BMN-450 for Fabry disease. Galafold revenue was $152M, up 10% YoY, while Pombility and Opfolda revenue was $49M, up 58% YoY.

finance.yahoo.com3 min
NOV 3
$BMRNMedAI 8/10

BioMarin Pharmaceutical Q3 Earnings Call Highlights

BioMarin (BMRN) reported Q3 earnings, with Voxzogo revenue up 12% YoY to $245M. The company lowered 2026 revenue guidance to $3.8B-$3.9B due to order timing and regional disruptions. Non-GAAP EPS guidance is $2.80-$3.10, including impacts from recent acquisitions. BioMarin also provided updates on its pipeline, including BMN 450 for Fabry disease and BMN 440 for hypophosphatasia.

finance.yahoo.com3 min
NOV 2
$BMRNMedAI 8/10

BioMarin: Q3 Earnings Snapshot

BioMarin Pharmaceutical Inc. reported a Q3 loss of $122.8 million, or 63 cents per share, but adjusted earnings of 23 cents per share beat expectations. Revenue of $1.02 billion missed forecasts. The company expects full-year earnings of $2.80 to $3.10 per share and revenue of $3.8 billion to $3.9 billion. Shares are down 3% YTD but up 7% over 12 months.

finance.yahoo.com2 min